CTI BioPharma
CTIC
#5622
Rank
HK$9.32 B
Marketcap
HK$70.74
Share price
0.00%
Change (1 day)
30.79%
Change (1 year)

Revenue for CTI BioPharma (CTIC)

Revenue in 2023 (TTM): HK$0.59 Billion

According to CTI BioPharma 's latest financial reports the company's current revenue (TTM ) is HK$0.58 Billion. In 2022 the company made a revenue of HK$0.42 Billion an increase over the revenue in the year 2021 that were of N/A. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for CTI BioPharma from 1997 to 2023

Annual revenue

Year Revenue Change
2023 (TTM) HK$0.59 B40.92%
2022 HK$0.42 B
2021 N/A
2020 N/A-100%
2019 HK$26.05 M-87.17%
2018 HK$0.20 B3.32%
2017 HK$0.19 B-55.87%
2016 HK$0.44 B256.38%
2015 HK$0.12 B-73.19%
2014 HK$0.46 B73.29%
2013 HK$0.26 B
2012 N/A
2011 N/A-100%
2010 HK$2.48 M300.22%
2009 HK$0.62 M-99.3%
2008 HK$88.34 M8821.34%
2007 HK$0.99 M59.15%
2006 HK$0.62 M-99.5%
2005 HK$0.12 B-45.75%
2004 HK$0.22 B19.81%
2003 HK$0.19 B45.68%
2002 HK$0.13 B170.97%
2001 HK$48.62 M1141.85%
2000 HK$3.91 M68%
1999 HK$2.33 M-97.72%
1998 HK$0.10 B11.84%
1997 HK$91.44 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Amgen
AMGN
HK$279.91 B 47,374.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
HK$373.78 B 63,295.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Incyte
INCY
HK$37.45 B 6,252.34%๐Ÿ‡บ๐Ÿ‡ธ USA
Baxter
BAX
HK$85.77 B 14,448.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
HK$462.39 B 78,322.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
HK$130.54 B 22,040.98%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Novartis
NVS
HK$438.67 B 74,299.82%๐Ÿ‡จ๐Ÿ‡ญ Switzerland